Author: Vikas Kumar
14 January 2023
According to a new report by UnivDatos Market Insights, the Asia Pacific Cancer Diagnostics Market is expected to reach USD ~XX billion by 2032 by growing at a CAGR of ~8%. The Asia-Pacific (APAC) market for cancer diagnostics is changing due to innovation, increasing cancer incidence, and improved access to healthcare. Cancer diagnostics in the world today have become an important field of medical science, and the Asia-Pacific region may be viewed as both a challenge and an opportunity in the global healthcare market. Therefore, the need for effective early detection of cancer is on the rise due to population growth, the heterogeneous healthcare needs, and the enhancement of the healthcare system in the region. This article examines the current state of affairs in cancer diagnostics in the Asia-Pacific region, with an emphasis on recent developments and growth strategies of companies that carry out diagnostics in this dynamically developing industry.
Access sample report (including graphs, charts, and figures):https://univdatos.com/get-a-free-sample-form-php/?product_id=31576
Rising Incidences of Cancer Boost the Demand
World Economic Forum, in 2023
· Asia currently accounts for 45% of all global breast cancer cases and 58% of cervical cancer deaths worldwide.
· Every dollar invested in interventions to help meet cervical cancer elimination targets could return over $3 to the economy.
· There are several actionable steps for change that regional governments could initiate to reduce the impact of cancer on women.
The increasing incidence of the disease is one of the key growth factors of the cancer diagnostics market in APAC. It is estimated that the region annually sustains almost 50 percent of the global new cancer cases as stipulated by the WHO. This increase is attributed to the following risk factors, which include; Age, Lifestyle changes, Pollution, and many other causes. The main specific types of cancer that are more common are lung cancer, breast cancer, colorectal cancer, and stomach cancer, and lung cancer is more acutely due to high smoking and pollution.
The increasing incidence of cancer in the Asia-Pacific region Asia Pacific has challenged healthcare stakeholders to adopt new methods of early diagnosis. Bodies and healthcare organizations are working to improve the scope and effectiveness of cancer screenings, and increasing their purchases of more precise diagnostic tools to lower cancer death rates. It is important to have an enhanced prognosis and to considerably cut down on the total amount needed for the treatment.
Technological Innovations: AI and Genomics
On Sept. 9, 2024, Roche announced the expansion of its digital pathology open environment with the integration of more than 20 advanced artificial intelligence (AI) algorithms from eight new collaborators. These strategic collaborations aim to support pathologists and scientists in cancer research and diagnosis by leveraging cutting-edge AI technology.
In July 2024, In a proof of concept study, scientists at Shanghai Jiao Tong University in China have developed a clinical laboratory test that utilizes artificial intelligence (AI) to diagnose three types of cancer from a single drop of dried blood. The paper-based test was able to identify patients with colorectal, gastric, and pancreatic cancers and distinguish between patients with and without cancer.
Innovations in technology are the driving force behind the changes that are taking place in the diagnosis of the disease. Asia-Pacific countries are quickly adopting Artificial Intelligence (AI) and genomics in general and specifically in diagnosis in the context of cancer. Diagnosis using medical imagery has become possible with the use of AI-diagnostic tools to determine images, cancerous cells, and the risk of cancer in patients. These tools can have a significant impact on increasing the precision of cancer diagnosis and at the same time the time and variety of analyses required before concluding and therefore the time it takes to begin the treatment process.
Genomic testing is another testing segment that is currently on an upward trend in the APAC region. The aggressive adoption of precision medicine means genomics is assuming increasing importance in identifying the genetic changes that underlie cancer. Known genetic variations are being addressed through biomarkers that are determined through new-generation sequencing and can be treated according to the prototype cancer of the patient.
Liquid Biopsy: A Game Changer
Liquid biopsy is also considered the most favorable in the diagnostics of cancer, including the Asia-Pacific region. Liquid biopsies change the traditional invasive and sometimes very challenging tissue biopsy by identifying tumor cells or pieces of DNA from the blood. By using such a noninvasive approach, patients do not have to undergo invasive procedures, cancer can be detected earlier, treatment response can be evaluated, and disease recurrence can be identified.
In Asia-Pacific, the significance of liquid biopsy has been increasing further as more healthcare providers look for ways to advance cancer care. The particularity of the technology is overstated in the recognition of lung cancer since it is among the most prevalent and fatal cancers in the area. Illumina is among the leading companies in the industry, alongside Qiagen and Roche, which has been working on creating the APAC market-relevant liquid biopsy solutions.
Growing Investments and Collaborations
The Asia-Pacific cancer diagnostics market is also growing due to a rise in investment activities and partnerships between international and domestic players. Worldwide players including Roche, Abbott Labs, and Siemens Healthineers for instance are in the process of increasing their market share in the region through joint ventures with healthcare providers and governments. Such collaborations are focused on enhancing the availability and adaption of sophisticated diagnostic equipment for addressing specific healthcare issues in each country in the region.
On August 6, 2024, Sysmex Corporation announced that it has expanded its strategic Alliance Agreement with QIAGEN N.V. (HQ: Venlo, The Netherlands; CEO: Thierry Bernard) to deepen their collaboration in genetic testing, including research and development, production, clinical development, and sales-marketing.
Specifically, China has emerged as the leading location for investment in cancer diagnostics. The current Chinese administration and its particular drive towards the Healthy China 2030 project have provided a positive backdrop for each domestic and international special player to enter and develop cancer diagnosing markets. Ventures are also building strategic partnerships to foster each other in technology, reach to the market, and regulation.
India is another major target market of APAC because of its growing healthcare sector and awareness of early diagnosis of cancer. Low-cost diagnostic solutions are being developed by domestic ventures to address the needs of the large population in India at the same time overseas ventures are exploring this sector through strategic partnerships.
Regulatory Landscape and Government Initiatives
The laws of various countries of the Asia-Pacific region act as the main influencers of the cancer diagnostics market. For example, Japan, Australia, South Korea, and many others have very strong bodies that regulate diagnostic tools to make sure that they are safe for human use. However, there may be stringent rules and regulations that may take some time to be followed especially for those companies in emerging markets planning to introduce the products.
To overcome these factors, some countries are reducing the time taken in regulatory approvals of cancer diagnostic devices. Chinese authorities have become more concentrated on supporting innovation and have implemented the policies of the National Medical Products Administration (NMPA) to speed up the approval of innovative diagnostic systems. Likewise, India’s Central Drugs Standard Control Organization (CDSCO) has integrated changes that will allow for faster approval of diagnostics.
Governments are also launching cancer screening programs intended to raise early detection ratios. For instance, Japan has a universal national cancer screening program for breast, cervical, and colorectal cancers. In China, the government has embarked on mass sensitization programs on lung cancer screening due to the high cases of smoking in the country.
Click here to view the Report Description & TOC– https://univdatos.com/get-a-free-sample-form-php/?product_id=31576
The Road Ahead
The prospects for diagnosis of cancer in the region are rather optimistic as the work on the new technologies is being conducted actively and understanding of the primary need for early diagnosis is being improved. This insight goes hand in with the region’s growing company innovation and partnerships to further enhance the diagnosis and treatment of cancer. It shows that government, healthcare organizations, and private entities need to find ways to solve these problems for innovative solutions to reach everybody.
In conclusion, it is perhaps inevitable to state that the Asia-Pacific cancer diagnostics market is ready for a revolution thanks to the increasing prevalence of cancer, new technologies, and investments. As a world, emphasis has shifted towards early diagnosis, as well as individualized therapy, which will be spearheaded by the region in the fight against cancer.
Get a call back
